BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shot up 5.6% on Wednesday . The company traded as high as $8.77 and last traded at $9.19. 40,864 shares were traded during mid-day trading, a decline of 93% from the average session volume of 562,598 shares. The stock had previously closed at $8.70.
A number of research firms recently weighed in on BCRX. Piper Jaffray Companies began coverage on BioCryst Pharmaceuticals in a report on Friday, November 16th. They issued an “overweight” rating and a $15.00 price target on the stock. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 7th. BidaskClub upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 16th. ValuEngine upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, October 12th. Finally, JMP Securities increased their target price on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, September 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $10.53.
The company has a current ratio of 2.00, a quick ratio of 1.98 and a debt-to-equity ratio of 0.43.
In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 11,198 shares of the stock in a transaction on Tuesday, November 20th. The stock was sold at an average price of $8.67, for a total transaction of $97,086.66. Following the transaction, the insider now owns 137,458 shares of the company’s stock, valued at approximately $1,191,760.86. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas R. Staab II sold 9,850 shares of the stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the transaction, the insider now directly owns 140,633 shares in the company, valued at approximately $1,018,182.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,850 shares of company stock worth $581,532. 4.50% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of BCRX. Janus Henderson Group PLC lifted its stake in shares of BioCryst Pharmaceuticals by 45.0% during the 2nd quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock worth $63,581,000 after purchasing an additional 3,441,498 shares during the period. VHCP Management III LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter worth $23,356,000. Baker BROS. Advisors LP lifted its stake in shares of BioCryst Pharmaceuticals by 7.8% during the 3rd quarter. Baker BROS. Advisors LP now owns 15,103,081 shares of the biotechnology company’s stock worth $115,237,000 after purchasing an additional 1,090,909 shares during the period. BlackRock Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 13.1% during the 3rd quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock worth $66,914,000 after purchasing an additional 1,013,905 shares during the period. Finally, VHCP Management II LLC lifted its stake in shares of BioCryst Pharmaceuticals by 31.9% during the 3rd quarter. VHCP Management II LLC now owns 3,249,164 shares of the biotechnology company’s stock worth $24,791,000 after purchasing an additional 784,923 shares during the period. 85.24% of the stock is currently owned by institutional investors.
WARNING: This piece was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.wkrb13.com/2018/11/23/biocryst-pharmaceuticals-bcrx-shares-up-5-6.html.
BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Story: What are the Benefits of Index Funds?
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.